Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, talks on the long-term safety and efficacy of tagraxofusp (TAG) monotherapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). TAG is a CD123-directed immunotherapy which received FDA approval for the treatment of BPDCN in 2018 and was also recently approved in the EU. Common treatment-emergent adverse events such as increased alanine and capillary leak syndrome were manageable, and a high rate of complete response allowed bridging of 51% of responders to stem cell transplantation (SCT). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.